Full Press Release Details
MARINA DEL REY, Calif. , Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian Varnum , PhD, President and Chief Development Officer, will present a corporate overview and host investor meetings at the Canaccord Genuity 39th Annual Growth Conference, being held August 7-8, 2019 at the InterContinental Boston Hotel.
The presentation is scheduled for Thursday, August 8th at 3:25pm Eastern Time .
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections using its proprietary bacteriophage-based technology. Armata's lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. The Company is also developing and advancing a broad pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa , leveraging its proprietary phage-specific GMP manufacturing capabilities. In collaboration with Merck, known as MSD outside of the United States and Canada , Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Media Contacts:
At the Company: Steve Martin Armata Pharmaceuticals, Inc. [email protected] (858) 800-2492
Investor Relations: Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.